Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

PMID:
29748390
2.

Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.

Sade JP, Báez CAV, Greco M, Martínez CH, Avitia MÁÁ, Palazzo C, Toriz NH, Trujillo PIB, Bastos DA, Schutz FA, Bella S, Nogueira L, Shore ND.

Med Oncol. 2018 Mar 19;35(4):56. doi: 10.1007/s12032-018-1105-8. Review.

3.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

PMID:
29437040
4.

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.

Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA.

Oncotarget. 2017 Aug 8;8(48):84572-84578. doi: 10.18632/oncotarget.20028. eCollection 2017 Oct 13. Review.

5.

First Brazilian Consensus of Advanced Prostate Cancer: Recommendations for Clinical Practice.

Sasse AD, Wiermann EG, Herchenhorn D, Bastos DA, Schutz FA, Maluf FC, Coura G Filho, Morbeck IAP, Cerci JJ, Smaletz O, Lima VS, Adamy A Jr, Campos FS, Carvalhal GF, Cezar LC, Dall'Oglio MF, Sadi MV, Reis RBD, Nogueira L.

Int Braz J Urol. 2017 May-Jun;43(3):407-415. doi: 10.1590/S1677-5538.IBJU.2016.0490.

6.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators.

N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.

7.

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.

Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE.

Cancer Med. 2014 Aug;3(4):835-44. doi: 10.1002/cam4.262. Epub 2014 May 21.

8.

Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.

Schutz FA, Buzaid AC, Sartor O.

Crit Rev Oncol Hematol. 2014 Sep;91(3):248-56. doi: 10.1016/j.critrevonc.2014.02.003. Epub 2014 Feb 15. Review.

PMID:
24613528
9.

Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.

Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE.

Clin Cancer Res. 2014 Apr 1;20(7):1873-83. doi: 10.1158/1078-0432.CCR-13-0759. Epub 2014 Jan 31.

10.

The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.

Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK.

Eur Urol. 2014 Apr;65(4):723-30. doi: 10.1016/j.eururo.2013.10.013. Epub 2013 Oct 26.

11.

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.

Harshman LC, Fougeray R, Choueiri TK, Schutz FA, Salhi Y, Rosenberg JE, Bellmunt J.

Br J Cancer. 2013 Nov 12;109(10):2548-53. doi: 10.1038/bjc.2013.617. Epub 2013 Oct 15.

12.

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.

Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, Culine S, Choueiri TK.

Ann Oncol. 2013 Jun;24(6):1466-72. doi: 10.1093/annonc/mdt007. Epub 2013 Feb 17.

PMID:
23419284
13.

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.

Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK.

Lancet Oncol. 2013 Jan;14(1):81-7. doi: 10.1016/S1470-2045(12)70517-X. Epub 2012 Dec 7. Erratum in: Lancet Oncol. 2013 Mar;14(3):e89.

14.

Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.

Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, Pedrosa I, Choueiri TK.

Eur J Cancer. 2012 Jul;48(10):1519-24. doi: 10.1016/j.ejca.2012.03.012. Epub 2012 Apr 5.

PMID:
22483544
15.
16.

Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.

Krajewski KM, Fougeray R, Bellmunt J, Pons F, Schutz FA, Rosenberg JE, Salhi Y, Choueiri TK.

Eur J Cancer. 2012 Jul;48(10):1495-502. doi: 10.1016/j.ejca.2011.11.018. Epub 2011 Dec 14.

PMID:
22176867
17.

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK.

JAMA. 2011 Dec 7;306(21):2359-66. doi: 10.1001/jama.2011.1745.

PMID:
22147380
18.

Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.

Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK.

J Clin Oncol. 2011 Sep 1;29(25):3450-6. doi: 10.1200/JCO.2010.34.4309. Epub 2011 Aug 1.

PMID:
21810682
19.

Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis.

Choueiri TK, Schutz FA, Hevelone ND, Nguyen PL, Lipsitz SR, Williams SB, Silverman SG, Hu JC.

Urology. 2011 Jul;78(1):93-8. doi: 10.1016/j.urology.2011.01.068. Epub 2011 May 7.

PMID:
21550636
20.

Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.

Schutz FA, Bellmunt J, Rosenberg JE, Choueiri TK.

Expert Opin Drug Saf. 2011 Jul;10(4):645-53. doi: 10.1517/14740338.2011.581660. Epub 2011 Apr 28. Review.

PMID:
21524237
21.

Haematologic toxicities associated with the addition of bevacizumab in cancer patients.

Schutz FA, Jardim DL, Je Y, Choueiri TK.

Eur J Cancer. 2011 May;47(8):1161-74. doi: 10.1016/j.ejca.2011.03.005. Epub 2011 Apr 4.

PMID:
21470847
22.

Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.

Schutz FA, Je Y, Choueiri TK.

Crit Rev Oncol Hematol. 2011 Nov;80(2):291-300. doi: 10.1016/j.critrevonc.2010.11.007. Epub 2011 Feb 20.

PMID:
21339073
23.

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.

Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK.

Eur Urol. 2011 May;59(5):856-62. doi: 10.1016/j.eururo.2011.01.038. Epub 2011 Feb 1.

PMID:
21306819
24.

Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls.

Bellmunt J, Choueiri TK, Schutz FA, Rosenberg JE.

Ann Oncol. 2011 Feb;22(2):245-7. doi: 10.1093/annonc/mdq684. No abstract available.

PMID:
21278220
25.

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA.

J Clin Oncol. 2011 Feb 20;29(6):632-8. doi: 10.1200/JCO.2010.31.9129. Epub 2011 Jan 4.

PMID:
21205755
26.

Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.

Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK.

Ann Oncol. 2011 Jun;22(6):1404-12. doi: 10.1093/annonc/mdq587. Epub 2010 Nov 29.

PMID:
21115602
27.

Preoperative and pathological staging of NSCLC: retrospective analysis of 291 cases.

Younes RN, Schutz FA, Gross JL.

Rev Assoc Med Bras (1992). 2010 Mar-Apr;56(2):237-41.

28.

Pazopanib: Clinical development of a potent anti-angiogenic drug.

Schutz FA, Choueiri TK, Sternberg CN.

Crit Rev Oncol Hematol. 2011 Mar;77(3):163-71. doi: 10.1016/j.critrevonc.2010.02.012. Epub 2010 Apr 24. Review.

PMID:
20456972
29.

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J.

J Clin Oncol. 2010 May 1;28(13):2280-5. doi: 10.1200/JCO.2009.27.2757. Epub 2010 Mar 29. Review.

PMID:
20351323
30.

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE.

J Clin Oncol. 2010 Apr 10;28(11):1850-5. doi: 10.1200/JCO.2009.25.4599. Epub 2010 Mar 15.

PMID:
20231682
31.

Neoadjuvant and adjuvant therapies in prostate cancer.

Schutz FA, Oh WK.

Urol Clin North Am. 2010 Feb;37(1):97-104, Table of Contents. doi: 10.1016/j.ucl.2009.11.012. Review.

PMID:
20152523
32.

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Je Y, Schutz FA, Choueiri TK.

Lancet Oncol. 2009 Oct;10(10):967-74. doi: 10.1016/S1470-2045(09)70222-0. Epub 2009 Sep 18. Review.

PMID:
19767240
33.

Aggressive multimodality treatment in transitional cell carcinoma of the parafallopian tube: report of 2 cases and review of the literature.

Maluf FC, Carvalho JP, Carvalho FM, Schütz FA, Feher O.

Gynecol Oncol. 2006 Aug;102(2):381-5. Epub 2006 Mar 13.

PMID:
16537088

Supplemental Content

Loading ...
Support Center